Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))
Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
The purposes of this study are:
- To determine the maximum tolerated dose (MTD) for the combination of oral vorinostat and
bortezomib in participants with advanced multiple myeloma
- To assess the safety and tolerability of this regimen and to document the participant's
clinical status (by anti-tumor activity) for this combination, as determined per
standard of care.